Document Type

Journal Article

Publication Title

Journal of Thoracic Oncology

Volume

17

Issue

7

First Page

921

Last Page

930

PubMed ID

35489694

Publisher

Elsevier

School

School of Medical and Health Science

Funders

Central Norway Regional Health Authority (RHA) / Norwegian University of Science and Technology (NTNU) / Dust Diseases Board of NSW Research Grant / Sir Charles Gairdner Hospital Research grant / iCARE Dust Disease Board PhD Scholarship

Comments

Louw, A., Panou, V., Szejniuk, W. M., Meristoudis, C., Chai, S. M., van Vliet, C., ... & Røe, O. D. (2022). BAP1 Loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: A validation study. Journal of Thoracic Oncology, 17(7), p.921-930. https://doi.org/10.1016/j.jtho.2022.04.008

Abstract

Introduction: Pleural mesothelioma (PM) is an aggressive malignancy with no identified predictive biomarkers. We assessed whether tumor BAP1 status is a predictive biomarker for survival in patients receiving first-line combination platinum and pemetrexed therapy. Methods: PM cases (n = 114) from Aalborg, Denmark, were stained for BAP1 on tissue microarrays. Demographic, clinical, and survival data were extracted from registries and medical records. Surgical cases were excluded. BAP1 status was associated with overall survival (OS) by Cox regression and Kaplan-Meier methods. Results were validated in an independent cohort from Perth, Australia (n = 234). Results: BAP1 loss was found in 62% and 60.3% of all Danish and Australian samples, respectively. BAP1 loss was an independent predictor of OS in multivariate analyses corrected for histological subtype, performance status, age, sex, and treatment (hazard ratio = 2.49, p < 0.001, and 1.48, p = 0.01, respectively). First-line platinum and pemetrexed-treated patients with BAP1 loss had significantly longer median survival than those with retained BAP1 in both the Danish (20.1 versus 7.3 mo, p < 0.001) and Australian cohorts (19.6 versus 11.1 mo, p < 0.01). Survival in patients with BAP1 retained and treated with platinum and pemetrexed was similar as in those with best supportive care. There was a higher OS in patients with best supportive care with BAP1 loss, but it was significant only in the Australian cohort (16.8 versus 8.3 mo, p < 0.01). Conclusions: BAP1 is a predictive biomarker for survival after first-line combination platinum and pemetrexed chemotherapy and a potential prognostic marker in PM. BAP1 in tumor is a promising clinical tool for treatment stratification.

DOI

10.1016/j.jtho.2022.04.008

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Included in

Oncology Commons

Share

 
COinS